LB Pharmaceuticals Enters $150M Private Placement

What Happened
LB Pharmaceuticals Inc. (LBRX) announced on July 28, 2026 that it entered a Securities Purchase Agreement to sell common stock and pre‑funded warrants in a private placement expected to close on or about July 30, 2026. The company agreed to issue 3,577,560 shares of common stock and pre‑funded warrants to purchase up to 715,513 additional shares, for estimated gross proceeds of approximately $150.0 million.

Key Details

• Securities: 3,577,560 common shares and pre‑funded warrants exercisable for up to 715,513 shares (total possible new shares = 4,293,073).
• Pricing: $34.94 per share; each pre‑funded warrant sold at $34.9399 (exercise price $0.0001). Pre‑funded warrants are immediately exercisable and do not expire.
• Ownership limits: Exercise of pre‑funded warrants is restricted to prevent a holder (with affiliates) from owning more than 4.99% or 9.99% of outstanding shares (holders may elect up to 19.99% with 61 days’ notice).
• Use of proceeds: Fund LB‑102 pipeline expansion (including potential trials for negative symptoms of schizophrenia and Alzheimer’s agitation/psychosis), plus working capital and general corporate purposes.
• Process and rights: Placement agents are Leerink Partners and Piper Sandler; the company agreed to file a Form S‑3 registration statement to register resale of the Shares and Warrant Shares within 90 days of closing and to use reasonable best efforts to have it declared effective.

Why It Matters
This transaction provides LB Pharmaceuticals with a significant cash infusion (about $150M gross) to advance its lead program LB‑102 into additional indications and support corporate operations. For existing shareholders, the issuance and potential exercise of the pre‑funded warrants could increase the company’s outstanding share count by up to 4,293,073 shares, which may dilute current holdings. The filing also gives investors resale protections via registration rights, which should make the new securities more liquid once the registration statement is effective.